Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:clinicalTrialPhase |
Phase 2
|
| gptkbp:clinicalTrialsGovURL |
https://clinicaltrials.gov/ct2/show/NCT02667587
|
| gptkbp:completedIn |
August 2017
|
| gptkbp:condition |
Asthma
|
| gptkbp:enrollment |
120
|
| https://www.w3.org/2000/01/rdf-schema#label |
NCT02667587
|
| gptkbp:intervention |
gptkb:Placebo
gptkb:Benralizumab Parallel Assignment |
| gptkbp:location |
gptkb:Canada
gptkb:Germany gptkb:Japan gptkb:United_States |
| gptkbp:mask |
Double (Participant, Investigator)
|
| gptkbp:officialName |
gptkb:A_Randomized,_Double-blind,_Parallel-group,_Placebo-controlled,_Phase_2_Study_to_Evaluate_the_Efficacy_and_Safety_of_Benralizumab_in_Patients_With_Uncontrolled_Asthma
|
| gptkbp:purpose |
Treatment
|
| gptkbp:sponsor |
gptkb:AstraZeneca
|
| gptkbp:startDate |
February 2016
|
| gptkbp:studyType |
Interventional
|
| gptkbp:bfsParent |
gptkb:glioblastoma
|
| gptkbp:bfsLayer |
5
|